Original communication| Volume 113, ISSUE 2, P192-199, February 1993

The role of eosinophils in interleukin-2/lymphokine-activated killer cell therapy

      This paper is only available as a PDF. To read, Please Download here.


      When interleukin-2 alone or in combination with lymphokine-activated killer (LAK) cells is administered to patients with cancer, peripheral or local eosinophilia is frequently seen. To evaluate the role of eosinophils in this setting, we studied the functional changes of human eosinophils induced by the supernatant of LAK cell cultures. The chemotactic activity, change in chemiluminescence, superoxide production, expression of leukocyte integrins (CD11/CD18 family), and adherent activity to plastic dishes were investigated after stimulation of eosinophils with LAK cell culture supernatant. The chemotactic activity of eosinophils in the supernatant of LAK cell cultures was increased significantly, and this activity was chemotactic rather than chemokinetic by checkerboard analysis. Both chemiluminescence and superoxide production of stimulated eosinophils increased significantly compared with resting. In addition, eosinophil-adherent activity to plastic dishes was also increased. Among leukocyte integrins, CD11b expression on stimulated eosinophils increased. Moreover, eosinophil antibody-dependent cellular cytotoxity against Raji cells was enhanced after stimulation with the supernatant of LAK cell cultures. These results suggest that the eosinophils activated by LAK cells may play an important role in the antitumor effect of interleukin-2/LAK cell therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rosenberg SA
        • Lotze MT
        • Muul LM
        • et al.
        Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
        N Engl J Med. 1985; 313: 1485-1492
        • West WH
        • Tauer KW
        • Yanelli JR
        • et al.
        Constant-infusion interleukin-2 in adoptive immunotherapy of advanced cancer.
        N Engl J Med. 1987; 316: 898-905
        • Rosenberg SA
        Immunotherapy of cancer using IL-2.
        Immunol Today. 1988; 9: 58-62
        • Silberstein DS
        • Schoof DD
        • Rodrick ML
        • Tai P
        • Spry CJF
        • David JR
        Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells.
        J Immunol. 1989; 142: 2162-2167
        • Sedwick JB
        • Warren EF
        • Sondel PM
        • Hank JA
        • Borden E
        • Busse WW
        The appearance of hypodense eosinophils during interleukin-2 treatment.
        J Allergy Clin Immunol. 1990; 85: 557-566
        • Forni G
        • Giovarelli M
        • Santoni A
        • Modesti A
        • Forni G
        Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.
        J Immunol. 1987; 138: 4033-4041
        • Thorne KJ
        • Richardson BA
        • Taverne J
        • Williamson DJ
        • Vadas MA
        • Butterworth AE
        A comparison of eosinophil-activating factor (EAF) with other monokines and lymphokines.
        Eur J Immunol. 1986; 16: 1143-1149
        • Silverstein DJ
        • David JR
        The regulation of human eosinophil function by cytokines.
        Immunol Today. 1987; 8: 380-385
        • Ishimitsu T
        • Uchiyama A
        • Morisaki T
        • Goya T
        • Yoshida T
        • Torisu M
        An eosinophil chemotactic factor in lymphokine-activated killer (LAK) cell supernatant [Abstract].
        in: Fed Proc. 4. 1990: 1945
        • Vadas MA
        • David JR
        • Butterworth A
        • Pisani NT
        • Siongok TA
        A new method for the purification of human eosinophils and neutrophils and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.
        J Immunol. 1979; 122: 1228-1236
        • Ward PA
        • Cochrane CG
        • Muller-Eberhard HJ
        The role of serum complement in chemotaxis of leukocytes in vitro.
        J Exp Med. 1965; 122: 327-347
        • Tanaka J
        • Torisu M
        Amsakis and eosinophils I. Detection of a soluble factor selectively chemotactic for eosinophils in the extract from Anisakis larvae.
        J Immunol. 1978; 120: 745-749
        • Litt M
        Studies in experimental eosinophilia. V. Eosinophils in lymph nodes of guinea pig following primary antigenic stimulation.
        Am J Pathol. 1963; 42: 529-547
        • Wang JM
        • Rambaldi A
        • Biondi A
        • Chen ZG
        • Sanderson CJ
        • Mantovani A
        Recombinant human interleukin 5 is a selective eosinophil chemoattractant.
        Eur J Immunol. 1989; 19: 701-705
        • Klebanoff SJ
        • Vadas MA
        • Harlan JM
        • et al.
        Stimulation of neutrophils by tumor necrosis factor.
        J Immunol. 1986; 136: 4220-4225
        • Lopez AF
        • Williamson DJ
        • Gamble JR
        • et al.
        Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival.
        J Clin Invest. 1986; 78: 1220-1228
        • Morisaki T
        • Torisu M
        Enhanced adherence activity of OK432-induced peritoneal neutrophils to tumor cells correlates with their increased expression of CD11b/CD18.
        Clin Immunol Immunopathol. 1991; 59: 474-486
        • Dallegri F
        • Partone F
        • Frumento G
        • Sacchetti C
        Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes: involvement of oxidative and nonoxidative mechanisms.
        J Natl Cancer Inst. 1984; 73: 331-339
        • Yamaguchi Y
        • Suda T
        • Shiozaki H
        • et al.
        Role of IL-5 in IL-2-induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2.
        J Immunol. 1990; 145: 873-877
        • Huland E
        • Huland H
        Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.
        Cancer Res. 1989; 49: 5469-5474
        • Miyasaka N
        • Darnell B
        • Baron S
        • Tala N
        Interleukin-2 enhances natural killing of normal monocytes.
        Cell Immunol. 1984; 84: 154-162
        • Jong EC
        • Klebanoff SJ
        Eosinophil-mediated mammalian tumor cell cytotoxity: role of the peroxidase system.
        J Immunol. 1980; 124: 1949-1953
        • Bass DA
        • Szejda P
        Mechanism of killing of newborn larvae of Trichinella spiralis by neutrophils and eosinophils: killing by generators of hydrogen peroxide in vitro.
        J Clin Invest. 1979; 64: 1558-1564
        • Capron M
        • Kazatchkine MD
        • Fischer E
        • et al.
        Functional role of the α-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxity against schistosomes.
        J Immunol. 1987; 139: 2059-2065
        • Walsh GM
        • Hartnell A
        • Wardlaw AJ
        • Kurihara K
        • Sanderson CJ
        • Kay AB
        IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leukocyte integrin (CD11/CD18)-dependent manner.
        Immunology. 1990; 71: 258-265
        • Lopez AF
        • Sanderson CJ
        • Gamble JR
        • Cambell HD
        • Young IG
        • Vadas MA
        Recombinant human interleukin 5 is a selective activator of human eosinophil function.
        J Exp Med. 1988; 167: 219-224
        • Rothenberg ME
        • Owen WF
        • Silverstein DS
        • et al.
        Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.
        J Clin Invest. 1988; 81: 1986-1992
        • Slungaard GM
        • Vercellotti GM
        • Walker G
        • Nelson RD
        • Jacob HS
        Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium.
        J Exp Med. 1990; 171: 2025-2041
        • Silverstein DS
        • David JR
        Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.
        in: Proc Natl Acad Sci USA. 83. 1986: 1055-1059
        • Valerius T
        • Repp R
        • Kalden JR
        • Platzer E
        Effects of IFN on human eosinophils in comparison with other cytokines: a novel class of eosinophil activators with delayed onset of action.
        J Immunol. 1990; 145: 2950-2958
        • Gemlo BT
        • Palladino WA
        • Jaffe HS
        • Espevik TP
        • Rayner AA
        Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells.
        Cancer Res. 1988; 48: 5864-5867
        • Kasid A
        • Director EP
        • Rosenberg SA
        Induction of cytokinemRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.
        J Immunol. 1989; 143: 736-739
        • Hartnell A
        • Moqbel R
        • Walsh GM
        • Bradley B
        • Kay AB
        Fcγ and CD11/CD18 receptor expression on normal density and low density human eosinophils.
        Immunology. 1990; 69: 264-270
        • Prestlow TP
        • Keith EF
        • Cryar AK
        • et al.
        Eosinophil infiltration of human colonic carcinomas as a prognostic indicator.
        Cancer Res. 1983; 43: 2997-3000
        • Iwasaki K
        • Torisu M
        • Fujimura T
        Malignant tumor and eosinophils. I. Prognotic significance in gastric cancer.
        Cancer. 1986; 58: 1321-1327
        • Kolb E
        • Muller EM
        Local responses in primary and secondary human lung cancers. II. Clinical correlations.
        Br J Cancer. 1979; 40: 410-416
        • Lowe D
        • Jorizzo J
        • Hutt M
        Tumor-associated eosinophilia: a review.
        J Clin Pathol. 1981; 34: 1343-1348
        • Pastrnak A
        • Jansa P
        Local eosinophilia in stroma of tumors related to prognosis.
        Neoplasma. 1984; 31: 323-326